We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) , along with its partner AstraZeneca PLC (AZN - Free Report) , announced that the FDA has accepted the biologics license application (“BLA”) for their promising monoclonal antibody, tezepelumab, which has been developed for the treatment of asthma.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected in the first quarter of 2022.
The BLA for tezepelumab was based on data from the PATHFINDER clinical program, which includes the pivotal phase III NAVIGATOR study which evaluated tezepelumab for treating patients with severe, uncontrolled asthma.
Data from the NAVIGATOR study showed that treatment with tezepelumab demonstrated superiority across all the primary and key secondary endpoints versus placebo for treating uncontrolled asthma in patients who received treatment with medium- or high-dose inhaled corticosteroids, and at least one additional controller medication with or without oral corticosteroids.
Per the company, tezepelumab is the first and only biologic treatment which has consistently and significantly reduced asthma exacerbations in patients across mid- to late-stage studies.
Shares of Amgen have rallied 5.8% so far this year against the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
We remind investors, that last November, tezepelumab met the primary endpoint in the phase III NAVIGATOR study which evaluated the candidate for treating patients with severe, uncontrolled asthma.
The FDA granted Breakthrough Therapy designation to tezepelumab for the treatment of patients with severe, uncontrolled asthma without an eosinophilic phenotype in September 2018.
Competitive pressure in the overall asthma market has intensified over the years. Upon potential approval, tezepelumab is likely to face stiff competition from GlaxoSmithKline’s (GSK - Free Report) Nucala and Regeneron (REGN - Free Report) /Sanofi’s blockbuster medicine Dupixent, which are approved for treating patients with severe asthma and some other indications as well.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
Amgen Inc. (AMGN - Free Report) , along with its partner AstraZeneca PLC (AZN - Free Report) , announced that the FDA has accepted the biologics license application (“BLA”) for their promising monoclonal antibody, tezepelumab, which has been developed for the treatment of asthma.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected in the first quarter of 2022.
The BLA for tezepelumab was based on data from the PATHFINDER clinical program, which includes the pivotal phase III NAVIGATOR study which evaluated tezepelumab for treating patients with severe, uncontrolled asthma.
Data from the NAVIGATOR study showed that treatment with tezepelumab demonstrated superiority across all the primary and key secondary endpoints versus placebo for treating uncontrolled asthma in patients who received treatment with medium- or high-dose inhaled corticosteroids, and at least one additional controller medication with or without oral corticosteroids.
Per the company, tezepelumab is the first and only biologic treatment which has consistently and significantly reduced asthma exacerbations in patients across mid- to late-stage studies.
Shares of Amgen have rallied 5.8% so far this year against the industry’s decline of 1.1%.
We remind investors, that last November, tezepelumab met the primary endpoint in the phase III NAVIGATOR study which evaluated the candidate for treating patients with severe, uncontrolled asthma.
The FDA granted Breakthrough Therapy designation to tezepelumab for the treatment of patients with severe, uncontrolled asthma without an eosinophilic phenotype in September 2018.
Competitive pressure in the overall asthma market has intensified over the years. Upon potential approval, tezepelumab is likely to face stiff competition from GlaxoSmithKline’s (GSK - Free Report) Nucala and Regeneron (REGN - Free Report) /Sanofi’s blockbuster medicine Dupixent, which are approved for treating patients with severe asthma and some other indications as well.
Zacks Rank
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>